Collaboration and License Agreements (Tables)

12 Months Ended

Sep. 30, 2023

Collaboration And License Agreements [Abstract]

Schedule of Revenue

The following table provides a summary of revenue recognized:

	Year Ended September 30,
	2023		2022		2021
	(in thousands)
GSK	$	29,657	$	124,764	$	—
Horizon	23,206		29,181		6,816
Takeda	162,516		85,834		90,784
Janssen	356		3,452		40,687
Amgen	25,000		—		—
Total	$	240,735	$	243,231	$	138,287

Schedule of Receivables and Contract Liabilities

The following table summarizes the balance of receivables and contract liabilities related to the Company’s collaboration and license agreements:

	September 30,
	2023		2022
	(in thousands)
Receivables included in accounts receivable	$	—	$	1,410
Contract liabilities included in deferred revenue	$	866	$	130,049